438 related articles for article (PubMed ID: 18558665)
1. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Dank M; Zaluski J; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Cisar L; Wang K; Bugat R
Ann Oncol; 2008 Aug; 19(8):1450-1457. PubMed ID: 18558665
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Pozzo C; Barone C; Szanto J; Padi E; Peschel C; Bükki J; Gorbunova V; Valvere V; Zaluski J; Biakhov M; Zuber E; Jacques C; Bugat R
Ann Oncol; 2004 Dec; 15(12):1773-81. PubMed ID: 15550582
[TBL] [Abstract][Full Text] [Related]
3. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Curran D; Pozzo C; Zaluski J; Dank M; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Bugat R
Qual Life Res; 2009 Sep; 18(7):853-61. PubMed ID: 19568958
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Koutras AK; Gerolymos MK; Kontogeorgou E; Iconomou G; Vourli G; Tsiata E; Makatsoris T; Chrysanthopoulos C; Kalofonos HP
J Chemother; 2007 Dec; 19(6):724-30. PubMed ID: 18230557
[TBL] [Abstract][Full Text] [Related]
7. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.
Koucky K; Wein A; Konturek PC; Albrecht H; Reulbach U; Männlein G; Wolff K; Ostermeier N; Busse D; Golcher H; Schildberg C; Janka R; Hohenberger W; Hahn EG; Siebler J; Neurath MF; Boxberger F
Med Sci Monit; 2011 May; 17(5):CR248-58. PubMed ID: 21525806
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Moehler M; Kanzler S; Geissler M; Raedle J; Ebert MP; Daum S; Flieger D; Seufferlein T; Galle PR; Hoehler T;
Ann Oncol; 2010 Jan; 21(1):71-7. PubMed ID: 19605504
[TBL] [Abstract][Full Text] [Related]
14. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Blanke CD; Haller DG; Benson AB; Rothenberg ML; Berlin J; Mori M; Hsieh YC; Miller LL
Ann Oncol; 2001 Nov; 12(11):1575-80. PubMed ID: 11822757
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Samalin E; Afchain P; Thézenas S; Abbas F; Romano O; Guimbaud R; Bécouarn Y; Desseigne F; Edeline J; Mitry E; Bouché O; Adenis A; Aparicio T; Dorval E; Kramar A; Ychou M
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):48-54. PubMed ID: 21634054
[TBL] [Abstract][Full Text] [Related]
17. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
18. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
[TBL] [Abstract][Full Text] [Related]
20. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
